论文部分内容阅读
目的:探讨奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者的临床疗效。方法:非盲法随机对照方法将患者分成试验组和对照组,各27例。试验组患者使用奥沙利铂联合替吉奥胶囊治疗,对照组患者使用奥沙利铂治疗,均为4个周期。评价两组治疗后的临床疗效和不良反应。结果:试验组:CR 1例,PR 11例,SD 10例,PD 5例。(CR+PR)RR 44.4%。中位疾病进展时间(TTP)9.5个月,中位生存期(MST)19.1个月。对照组:CR 0例,PR 5例,SD 8例,PD 15例。(CR+PR)RR 18.5%。中位疾病进展时间(TTP)8.6个月,中位生存期(MST)16.9个月。主要不良反应为血液毒性、胃肠道反应、外周神经炎及肝功能异常。试验组白细胞下降15例,对照组12例,试验组贫血发生为13例,对照组的为21例,试验组恶心、呕吐发生为18例,对照组为24例,试验组便秘发生为8例,对照组为15例,差异有统计学意义(P<0.05)。结论:奥沙利铂联合替吉奥胶囊治疗晚期大肠癌患者相比单独使用奥沙利铂更加有效,更具优越性,不良反应更少,患者的生存质量得以改善,值得临床上推广应用。
Objective: To investigate the clinical efficacy of oxaliplatin combined with tigiao capsule in the treatment of patients with advanced colorectal cancer. Methods: The patients were divided into experimental group and control group by non-blinded randomized controlled trial, 27 cases in each. Patients in the test group were treated with oxaliplatin in combination with tioguanuo capsules, while patients in the control group were treated with oxaliplatin, both of which were in 4 cycles. Evaluation of clinical efficacy and adverse reactions after treatment in both groups. Results: The experimental group: CR 1 cases, PR 11 cases, SD 10 cases, PD 5 cases. (CR + PR) RR 44.4%. Median disease progression time (TTP) 9.5 months, median survival (MST) 19.1 months. Control group: CR 0 cases, PR 5 cases, SD 8 cases, PD 15 cases. (CR + PR) RR 18.5%. The median progression time (TTP) was 8.6 months, and the median survival time (MST) was 16.9 months. The main adverse reactions were hematotoxicity, gastrointestinal reactions, peripheral neuritis and liver dysfunction. 15 cases of leukopenia in the experimental group, 12 cases in the control group, anemia in the experimental group was 13 cases, 21 cases in the control group, nausea and vomiting in the experimental group was 18 cases, the control group was 24 cases, the experimental group was 8 cases of constipation , 15 cases in the control group, the difference was statistically significant (P <0.05). Conclusion: The combination of oxaliplatin and tioguan capsules in the treatment of patients with advanced colorectal cancer is more effective and superior than oxaliplatin alone in treating patients with fewer adverse reactions and improving the quality of life of patients. It is worth to be popularized clinically.